JP2020515583A - アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 - Google Patents

アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 Download PDF

Info

Publication number
JP2020515583A
JP2020515583A JP2019553272A JP2019553272A JP2020515583A JP 2020515583 A JP2020515583 A JP 2020515583A JP 2019553272 A JP2019553272 A JP 2019553272A JP 2019553272 A JP2019553272 A JP 2019553272A JP 2020515583 A JP2020515583 A JP 2020515583A
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
ring
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515583A5 (enExample
Inventor
エイ デロング、ミッチェル
エイ デロング、ミッチェル
エム スターディバント、ジル
エム スターディバント、ジル
エル リコロウィック、シンシア
エル リコロウィック、シンシア
コルニーロフ、アンドリー
Original Assignee
アエリエ ファーマシューティカルズ インコーポレイテッド
アエリエ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエリエ ファーマシューティカルズ インコーポレイテッド, アエリエ ファーマシューティカルズ インコーポレイテッド filed Critical アエリエ ファーマシューティカルズ インコーポレイテッド
Publication of JP2020515583A publication Critical patent/JP2020515583A/ja
Publication of JP2020515583A5 publication Critical patent/JP2020515583A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2019553272A 2017-03-31 2018-03-30 アリールシクロプロピル−アミノ−イソキノリニルアミド化合物 Pending JP2020515583A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762480239P 2017-03-31 2017-03-31
US62/480,239 2017-03-31
US201862643131P 2018-03-14 2018-03-14
US62/643,131 2018-03-14
PCT/US2018/025494 WO2018183911A1 (en) 2017-03-31 2018-03-30 Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Publications (2)

Publication Number Publication Date
JP2020515583A true JP2020515583A (ja) 2020-05-28
JP2020515583A5 JP2020515583A5 (enExample) 2021-05-06

Family

ID=63678156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553272A Pending JP2020515583A (ja) 2017-03-31 2018-03-30 アリールシクロプロピル−アミノ−イソキノリニルアミド化合物

Country Status (11)

Country Link
US (3) US10858339B2 (enExample)
EP (1) EP3609871A4 (enExample)
JP (1) JP2020515583A (enExample)
KR (1) KR20190135027A (enExample)
CN (1) CN110506037A (enExample)
AU (2) AU2018243687C1 (enExample)
BR (1) BR112019020078A2 (enExample)
CA (1) CA3057872A1 (enExample)
MX (1) MX2019011784A (enExample)
SG (1) SG11201908179UA (enExample)
WO (1) WO2018183911A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
EP3461484B9 (en) 2013-03-15 2021-06-09 Aerie Pharmaceuticals, Inc. Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) * 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
CA3062170A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CA3112391A1 (en) * 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020176579A1 (en) * 2019-02-26 2020-09-03 Aerie Pharmaceuticals, Inc. Thienyl cyclopropyl-amino-isoquinolinyl amide compounds
US12459956B2 (en) 2019-09-13 2025-11-04 Alcon Inc. Heterobicyclic carboxamides and uses thereof
CN113072538B (zh) * 2020-01-06 2024-04-05 广东东阳光药业股份有限公司 RORγt抑制剂及其在药物中的应用
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN115557898B (zh) * 2021-07-01 2024-08-20 诸葛国琴 一种咪唑类化合物、其中间体及应用
CN115677676B (zh) * 2022-10-19 2024-10-01 黑龙江中医药大学 一种治疗银屑病的药物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP2008528624A (ja) * 2005-01-28 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー フェニル置換ピロリドン
JP2010515739A (ja) * 2007-01-10 2010-05-13 アエリエ・ファーマシューティカルズ・インコーポレーテッド ６−アミノイソキノリン化合物
JP2012525442A (ja) * 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 二重作用阻害剤およびその使用方法
WO2014058071A1 (ja) * 2012-10-12 2014-04-17 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途

Family Cites Families (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2623228C3 (de) 1976-05-24 1981-09-10 Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide
JPS5587771A (en) 1978-12-27 1980-07-02 Teikoku Hormone Mfg Co Ltd 1-phenylisoquinoline derivative
US4456757A (en) 1981-03-20 1984-06-26 Asahi Kasei Kogyo Kabushiki Kaisha Isoquinolinesulfonyl derivatives and process for the preparation thereof
JPS5993054A (ja) 1982-11-18 1984-05-29 Asahi Chem Ind Co Ltd イソキノリンスルホン酸アミド誘導体
DK8386A (da) 1986-01-15 1987-07-09 Tpo Pharmachim Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme
DE3766472D1 (de) 1986-10-28 1991-01-10 Smith Kline French Lab Tetrahydroisochinolin-2-yl-derivate von carbonsaeuren als thromboxan a2-antagonisten.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5591887A (en) 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH01139528A (ja) 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
DE68929435T2 (de) 1988-09-06 2003-07-17 Pharmacia Ab, Stockholm Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension
ES2075082T3 (es) 1989-03-28 1995-10-01 Nisshin Flour Milling Co Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular.
KR920008026A (ko) 1990-10-24 1992-05-27 오노 화아마슈티칼 캄파니 리미팃드 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물
EP0630373A1 (en) 1992-03-12 1994-12-28 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6124344A (en) 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698733A (en) 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
WO1998021180A1 (en) 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
EP0869794B1 (en) 1995-12-22 2004-08-11 Alcon Laboratories, Inc. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5866602A (en) 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
US5814660A (en) 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
US6586425B2 (en) 1996-02-21 2003-07-01 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
EP0930296B2 (en) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorinated prostaglandin derivatives and medicines
US6353000B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6353014B1 (en) 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 15-ketal postaglandins for the treatment of glaucoma or ocular hypertension
EP0938472B1 (en) 1996-11-12 2001-06-27 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives
CA2269853A1 (en) 1996-11-12 1998-05-22 Paul W. Zinke Use of cis-.delta.4 analogs of prostaglandins as ocular hypotensives
AU6545498A (en) 1997-03-07 1998-09-22 Alcon Laboratories, Inc. 13-thia prostaglandins for use in glaucoma therapy
WO1998050024A1 (en) 1997-05-09 1998-11-12 The Mount Sinai School Of Medicine Of The City University Of New York 8-iso-prostaglandins for glaucoma therapy
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
JP2001515883A (ja) 1997-09-09 2001-09-25 ザ プロクター アンド ギャンブル カンパニー Ｆｐアゴニストとして有用な、芳香族のあるｃ１６〜ｃ２０が置換されたテトラヒドロプロスタグランジン類
ID23971A (id) 1997-09-09 2000-06-14 Procter & Gamble Prostaglandin tetrahidro tersubstitusic c<16>-c<20> aromatik yang berguna sebagai agonis fp
US6048895A (en) 1997-09-09 2000-04-11 The Procter & Gamble Company Aromatic C16-C20 substituted tetrahydro prostaglandins useful as FP agonists
US5877211A (en) 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
WO1999032441A1 (en) 1997-12-22 1999-07-01 Alcon Laboratories, Inc. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension
EP1011728B1 (en) 1998-07-14 2004-12-29 Alcon Manufacturing, Ltd. Polypropylene containers for prostaglandin products
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6720175B1 (en) 1998-08-18 2004-04-13 The Johns Hopkins University School Of Medicine Nucleic acid molecule encoding homer 1B protein
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
JP2003500385A (ja) 1999-05-24 2003-01-07 コア・セラピューティクス，インコーポレイテッド Ｘａ因子阻害剤
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
MXPA02004985A (es) 1999-11-26 2003-10-14 Shionogi & Co Antagonistas del neuropeptido y, y5.
JP4234344B2 (ja) 1999-12-28 2009-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有複素環化合物
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
KR100767000B1 (ko) 2000-02-03 2007-10-15 에자이 알앤드디 매니지먼트 가부시키가이샤 인테그린 발현 저해제
US6362177B1 (en) 2000-05-16 2002-03-26 Teijin Limited Cyclic amine derivatives and their use as drugs
US6908741B1 (en) 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
US6323228B1 (en) 2000-09-15 2001-11-27 Abbott Laboratories 3-substituted indole angiogenesis inhibitors
EP1335901B1 (en) 2000-10-17 2010-04-14 Merck Serono SA Pharmaceutically active sulfanilide derivatives
US7163800B2 (en) 2000-11-03 2007-01-16 Molecular Devices Corporation Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity
EP1387680A4 (en) 2001-03-05 2010-01-13 Transtech Pharma Inc AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003245773A1 (en) 2002-02-15 2003-09-04 Glaxo Group Limited Vanilloid receptor modulators
AU2003217870A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pini-modulating compounds and methods of use thereof
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
ATE420109T1 (de) 2002-05-13 2009-01-15 Molecular Devices Corp Konstitutiv translozierende zelllinie
WO2004019951A1 (ja) 2002-08-29 2004-03-11 Santen Pharmaceutical Co., Ltd. Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
US7345158B2 (en) 2002-08-30 2008-03-18 Anges Mg, Inc. Actin related cytoskeletal protein “LACS”
EP1550660A1 (en) 2002-09-12 2005-07-06 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
WO2004037784A2 (en) * 2002-10-21 2004-05-06 Irm Llc Pyrrolidones with anti-hiv activity
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP4400566B2 (ja) 2003-06-12 2010-01-20 アステラス製薬株式会社 ベンズアミド誘導体又はその塩
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
WO2005037198A2 (en) 2003-10-06 2005-04-28 Glaxo Group Limited Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
DE10348023A1 (de) 2003-10-15 2005-05-19 Imtm Gmbh Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
ES2426288T3 (es) 2003-10-15 2013-10-22 Ube Industries, Ltd. Novedoso derivado de imidazol
SE0400284D0 (sv) 2004-02-10 2004-02-10 Astrazeneca Ab Novel compounds
JP2005227441A (ja) 2004-02-12 2005-08-25 Konica Minolta Medical & Graphic Inc 光熱写真画像形成材料
EP1718638A4 (en) 2004-02-20 2009-04-22 Smithkline Beecham Corp NEW COMPOUNDS
US20080096238A1 (en) 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP2008503492A (ja) 2004-06-17 2008-02-07 スミスクライン・ビーチャム・コーポレイション Ｒｈｏ−キナーゼの新規阻害剤
ES2568506T3 (es) 2004-06-18 2016-04-29 Tobii Ab Control ocular de aparato computador
NZ552866A (en) 2004-08-26 2010-06-25 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
WO2006041119A1 (ja) 2004-10-13 2006-04-20 Eisai R & D Management Co., Ltd. ヒドラジド誘導体
UY29198A1 (es) 2004-11-09 2006-05-31 Cancer Rec Tech Ltd Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
GB0425026D0 (en) 2004-11-12 2004-12-15 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
CA2593718A1 (en) 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
AU2006204724A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
EP1851197A2 (en) 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives
AU2006249596A1 (en) 2005-05-25 2006-11-30 Wyeth Methods of synthesizing 6-alkylaminoquinoline derivatives
WO2007008942A2 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
TW200738682A (en) 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
BRPI0620463A2 (pt) 2005-12-22 2011-11-16 Alcon Res Ltd composição farmacêutica oftálmica, compostos, e seus usos
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
CA2633624C (en) 2005-12-30 2013-11-19 Novartis Ag 3,5-substituted piperidine compounds as renin inhibitors
BRPI0707312B1 (pt) 2006-01-27 2022-06-07 Shanghai Hengrui Pharmacetical Co., Ltd Inibidores de pirrolo [3,2-c] piridina-4-ona 2-indolinona proteína cinase, seu uso e seu processo de fabricação, intermediário e seus processos de fabricação, composição farmacêutica e seu uso
JP5476559B2 (ja) 2006-02-10 2014-04-23 国立大学法人九州大学 リン酸化酵素の新規基質ポリペプチド
WO2007101204A1 (en) 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
JP2009528365A (ja) 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体
JP2007246466A (ja) 2006-03-17 2007-09-27 Osaka Univ 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法
TW200815398A (en) 2006-06-08 2008-04-01 Ube Industries A novel indazole derivative having spirocyclic structure in the side chain
WO2008036459A2 (en) 2006-07-20 2008-03-27 Borchardt Allen J Inhibitors of rho kinase
CN101790527A (zh) 2006-07-20 2010-07-28 凯利普西斯公司 Rho激酶的苯并噻吩抑制剂
US20090247552A1 (en) 2006-07-31 2009-10-01 Shirou Sawa Aqueous liquid preparation containing amide compound
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
US8949825B1 (en) 2006-10-17 2015-02-03 Manageiq, Inc. Enforcement of compliance policies in managed virtual systems
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008049919A2 (en) 2006-10-26 2008-05-02 Devgen N.V. Rho kinase inhibitors
US8071779B2 (en) 2006-12-18 2011-12-06 Inspire Pharmaceuticals, Inc. Cytoskeletal active rho kinase inhibitor compounds, composition and use
WO2008079945A2 (en) 2006-12-20 2008-07-03 University Of South Florida Rock inhibitors and uses thereof
AR064420A1 (es) 2006-12-21 2009-04-01 Alcon Mfg Ltd Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop).
KR20090103903A (ko) 2006-12-27 2009-10-01 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체
RU2457203C2 (ru) 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
CN101611012B (zh) 2006-12-27 2012-11-14 塞诺菲-安万特股份有限公司 环烷基胺取代的异喹啉衍生物
WO2008077552A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
MX2009005862A (es) 2006-12-27 2009-06-17 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
AU2007338412B2 (en) 2006-12-27 2013-03-14 Sanofi-Aventis Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives
WO2008105058A1 (ja) 2007-02-27 2008-09-04 Asahi Kasei Pharma Corporation スルホンアミド化合物
CA2683647A1 (en) 2007-04-10 2008-10-16 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2009006567A2 (en) 2007-07-05 2009-01-08 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
PT2217572E (pt) * 2007-11-16 2014-02-17 Vertex Pharma Moduladores de isoquinolina de transportadores de cassete de ligação a atp
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
PL2318006T3 (pl) 2008-08-15 2017-06-30 Nivalis Therapeutics, Inc. Nowe inhibitory pirolowe reduktazy S-nitrozoglutationu jako środki terapeutyczne
CA2764124C (en) 2009-06-19 2016-12-13 D. Western Therapeutics Institute, Inc. Substituted isoquinoline derivative
WO2011085351A2 (en) * 2010-01-11 2011-07-14 The Johns Hopkins University Method of treating kcnq related disorders
FR2961694B1 (fr) 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
CA2812164A1 (en) 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TW202446398A (zh) 2011-02-04 2024-12-01 日商興和股份有限公司 具眼壓下降作用之醫藥
JP2013035802A (ja) 2011-08-10 2013-02-21 D Western Therapeutics Institute Inc 緑内障又は高眼圧症の予防又は治療剤
EP2671883A1 (en) 2012-06-05 2013-12-11 Bioprojet New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
JP2014019650A (ja) 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
RU2015106915A (ru) * 2012-08-01 2016-09-20 Мерк Шарп И Доум Корп. МОДУЛЯТОРЫ α7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ИХ ПРИМЕНЕНИЕ
EP3461484B9 (en) 2013-03-15 2021-06-09 Aerie Pharmaceuticals, Inc. Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders
WO2016009076A1 (en) 2014-07-17 2016-01-21 Merck Patent Gmbh Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors
WO2016123627A1 (en) 2015-01-30 2016-08-04 Vanderbilt University Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
US9770466B2 (en) 2015-07-02 2017-09-26 Veloce Biopharma, Llc Ophthalmic composition and methods of use
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002019A (es) 2016-08-19 2019-07-04 Aerie Pharmaceuticals Inc Compuestos de beta-amino-isoquinolinil amida.
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
JP2020515583A (ja) * 2017-03-31 2020-05-28 アエリエ ファーマシューティカルズ インコーポレイテッド アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
JP7470046B2 (ja) 2018-03-30 2024-04-17 アエリエ ファーマシューティカルズ インコーポレイテッド ６－アミノイソキノリンのモノ酸塩及びその使用
CA3112391A1 (en) * 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528624A (ja) * 2005-01-28 2008-07-31 アイアールエム・リミテッド・ライアビリティ・カンパニー フェニル置換ピロリドン
WO2007008926A1 (en) * 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP2010515739A (ja) * 2007-01-10 2010-05-13 アエリエ・ファーマシューティカルズ・インコーポレーテッド ６−アミノイソキノリン化合物
JP2012525442A (ja) * 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 二重作用阻害剤およびその使用方法
WO2014058071A1 (ja) * 2012-10-12 2014-04-17 武田薬品工業株式会社 シクロプロパンアミン化合物およびその用途

Also Published As

Publication number Publication date
AU2018243687A1 (en) 2019-09-26
US11312700B2 (en) 2022-04-26
US20180327381A1 (en) 2018-11-15
MX2019011784A (es) 2019-11-18
EP3609871A4 (en) 2021-01-06
US20230130470A1 (en) 2023-04-27
AU2018243687C1 (en) 2020-12-24
BR112019020078A2 (pt) 2020-04-28
SG11201908179UA (en) 2019-10-30
CN110506037A (zh) 2019-11-26
WO2018183911A1 (en) 2018-10-04
EP3609871A1 (en) 2020-02-19
CA3057872A1 (en) 2018-10-04
US12018012B2 (en) 2024-06-25
KR20190135027A (ko) 2019-12-05
AU2020250183A1 (en) 2020-11-05
US10858339B2 (en) 2020-12-08
US20210002253A1 (en) 2021-01-07
AU2018243687B2 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP2020515583A (ja) アリールシクロプロピル−アミノ−イソキノリニルアミド化合物
AU2017312712B2 (en) Beta-amino-isoquinolinyl amide compounds
KR20140040774A (ko) 이미다조피리딘 화합물
KR20020081455A (ko) 아미드 화합물 및 그의 용도
KR20240031347A (ko) 아제티디닐 피리미딘 및 그의 용도
KR101760158B1 (ko) 축환 피리딘 화합물
JPWO2006057270A1 (ja) 含窒素３環化合物
AU2019234858A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
US12459956B2 (en) Heterobicyclic carboxamides and uses thereof
WO2020176579A1 (en) Thienyl cyclopropyl-amino-isoquinolinyl amide compounds
TW202233609A (zh) 2-羥環烷-1-胺甲醯基衍生物
HK40007624A (en) Beta-amino-isoquinolinyl amide compounds
JPWO2001056988A1 (ja) キナーゼ阻害活性を有する窒素含有化合物およびそれを含む医薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927